Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 986310, 11 pages
Research Article

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, 431 80 Mölndal, Sweden
2Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 205 02 Malmö, Sweden
3Forensic Psychiatry, Institute of Neuroscience and Psychology, The Sahlgrenska Academy at University of Gothenburg, 422 50 Gothenburg, Sweden
4Department of Neurobiology, Karolinska Institute, Caring Sciences and Society, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
5Department of Geriatric Medicine, Karolinska Institute, Memory Clinic, M51, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden

Received 15 March 2010; Accepted 7 June 2010

Academic Editor: Lucilla Parnetti

Copyright © 2010 Maria Bjerke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of -amyloid ( ). However, a high discrepancy between different centers in measured levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured level. Methods. Aliquots of CSF samples were either treated differently prior to measurement or analyzed using different commercially available xMAP or ELISA assays. Results. Confounding factors affecting CSF levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.